Ono to Acquire Deciphera for $2.4 Billion

Japan’s Ono Pharmaceutical agreed to acquire US cancer-therapy company Deciphera Pharmaceuticals for approximately $2.4 billion. Deciphera focuses on innovative cancer therapeutics, and specializes in kinase biology.

Under the terms of the definitive merger agreement, Ono will acquire all available shares of Deciphera for $25.60 per share in cash. Deciphera will continue to operate as a wholly owned subsidiary of Ono.

With this deal, Ono acquires ownership of Qinlock (ripretinib), an already approved cancer therapy, as well as another drug candidate that is currently in Phase 3 trials. Qinlock, a KIT inhibitor, is approved in over 40 countries for the treatment of fourth-line gastrointestinal stromal tumor.

The closing of the proposed deal is subject to customary closing conditions, including US antitrust clearance and the tender of a majority of Deciphera’s outstanding shares of common stock. The companies expect to complete the acquisition in the third quarter of 2024. The boards of directors of both companies have unanimously approved the acquisition.

Gyo Sagara, CEO of Ono, commented: “We expect that this acquisition of Deciphera will not only expand Ono’s targeted oncology portfolio, but also accelerate Ono’s business development in the United States and Europe, and strengthen kinase drug discovery research.”

Deciphera CEO Steven L. Hoerter added: “Deciphera and Ono share a deep commitment to improve the lives of people living with cancer, and the transaction announced today enables us to make even greater impact for patients. Together, we expect to advance and accelerate each organization’s important work through combined research and development capabilities and a global commercial footprint.”

© royaltystockphoto.com/Shutterstock
© royaltystockphoto.com/Shutterstock

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.